Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Korea.
J Korean Med Sci. 2021 Dec 27;36(50):e344. doi: 10.3346/jkms.2021.36.e344.
The coronavirus disease 2019 (COVID-19) pandemic is being overcome by widespread inoculation with various COVID-19 vaccines, but concerns about the safety of the vaccines are a major hurdle to widespread vaccination. We report the first case of adult-onset Still's disease (AOSD) developing in a 36-year-old, previously healthy woman after the first dose of BNT162b2 mRNA COVID-19 vaccine (Pfizer). She visited our hospital due to high spiking fever and sore throat that developed 10 days after vaccination. Based on thorough investigations and changes in symptoms and signs after admission, she was diagnosed with AOSD and treated with high dose steroids and tocilizumab. This report suggests the possibility that AOSD could be triggered by COVID-19 vaccines through activation of the innate immune system.
新型冠状病毒病 2019（COVID-19）大流行正在通过广泛接种各种 COVID-19 疫苗得到控制，但对疫苗安全性的担忧是广泛接种疫苗的主要障碍。我们报告了首例在接种 BNT162b2 mRNA COVID-19 疫苗（辉瑞）第一剂后，一名 36 岁、既往健康的女性发生成人Still 病（AOSD）的病例。她因接种疫苗 10 天后出现高热和咽痛而到我院就诊。根据全面的调查和入院后症状和体征的变化，她被诊断为 AOSD，并接受了大剂量类固醇和托珠单抗治疗。本报告提示 COVID-19 疫苗可能通过激活固有免疫系统引发 AOSD。
